Skip to main content
. 2019 May 1;15(5):e1006980. doi: 10.1371/journal.pcbi.1006980

Fig 7.

Fig 7

(A) ELISA revealed improved antigen binding with VH clone 1 and VL clone 16, as well as the combination clone with both variable domains. (B) Fab fragments of C1, C16, and C1-16 showed improved KD values for muCCL20 when compared with parental AB1. (C) A cell-based β-arrestin assay demonstrated that the affinity-matured variants led to improved CCR6 receptor blocking activity when compared with the parental AB1 clone.